Trade CureVac N.V. - CVAC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.65 |
| Open | 2.62 |
| 1-Year Change | -53.3% |
| Day's Range | 2.48 - 2.63 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 2.52 | -0.12 | -4.55% | 2.64 | 2.65 | 2.48 |
| Nov 14, 2024 | 2.65 | -0.06 | -2.21% | 2.71 | 2.77 | 2.60 |
| Nov 13, 2024 | 2.72 | -0.04 | -1.45% | 2.76 | 2.86 | 2.70 |
| Nov 12, 2024 | 2.85 | -0.04 | -1.38% | 2.89 | 2.94 | 2.73 |
| Nov 11, 2024 | 2.77 | -0.04 | -1.42% | 2.81 | 2.82 | 2.71 |
| Nov 8, 2024 | 2.81 | 0.06 | 2.18% | 2.75 | 2.92 | 2.75 |
| Nov 7, 2024 | 2.80 | -0.02 | -0.71% | 2.82 | 2.87 | 2.76 |
| Nov 6, 2024 | 2.83 | 0.07 | 2.54% | 2.76 | 2.85 | 2.68 |
| Nov 5, 2024 | 2.92 | 0.27 | 10.19% | 2.65 | 2.93 | 2.63 |
| Nov 4, 2024 | 2.69 | -0.11 | -3.93% | 2.80 | 2.85 | 2.61 |
| Nov 1, 2024 | 2.75 | 0.04 | 1.48% | 2.71 | 2.81 | 2.71 |
| Oct 31, 2024 | 2.72 | -0.07 | -2.51% | 2.79 | 2.82 | 2.69 |
| Oct 30, 2024 | 2.77 | -0.04 | -1.42% | 2.81 | 2.92 | 2.75 |
| Oct 29, 2024 | 2.86 | 0.04 | 1.42% | 2.82 | 3.01 | 2.82 |
| Oct 28, 2024 | 2.80 | 0.10 | 3.70% | 2.70 | 2.80 | 2.65 |
| Oct 25, 2024 | 2.74 | 0.06 | 2.24% | 2.68 | 2.74 | 2.68 |
| Oct 24, 2024 | 2.70 | 0.02 | 0.75% | 2.68 | 2.74 | 2.65 |
| Oct 23, 2024 | 2.68 | -0.02 | -0.74% | 2.70 | 2.75 | 2.66 |
| Oct 22, 2024 | 2.74 | 0.02 | 0.74% | 2.72 | 2.78 | 2.62 |
| Oct 21, 2024 | 2.75 | 0.00 | 0.00% | 2.75 | 2.84 | 2.68 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CureVac N.V. Company profile
CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).
The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’
CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.
The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.
CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.
According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.
According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.
You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.
| Industry: | Biotechnology & Medical Research (NEC) |
Friedrich-Miescher-Str. 15
TUEBINGEN
BADEN-WUERTTEMBERG 72076
DE
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com